%asset_metadata_dcterms.description%

Priority Research Centre for
BIOINFORMATICS, BIOMARKER DISCOVERY AND INFORMATION-BASED MEDICINE

About us

The Priority Research Centre for Bioinformatics, Biomarker Discovery and Information-Based Medicine (CIBM) is committed to shortening the process of obtaining novel discoveries to achieve distinctively better outcomes in clinical practice and translational individualised medicine.

A scientific revolution is in the making. In a few years time, all known genetic risk factors for diseases could be routinely determined at birth. Using large-scale molecular interrogation methods, powered by advances in mathematics and computer science, a patient's particular disease subtypes could be identified and the best available treatment selected. Outcomes of patient tailored treatments will be valuable for the development of new diagnostic approaches and drug designs that specifically target aberrant molecular pathways present in diseased cells with minimal interference on healthy ones. This is the promise of personalised information-based medicine

The core aim of the research conducted by this Centre is the delivery of "bench-to-bedside" research by combining the often disparate disciplines of bioinformatics, molecular and genetic analysis, clinical information and population data. The Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM) aims to find methodologies that will shorten the process of obtaining novel discoveries and to use them to obtain distinctively better outcomes in clinical practice and translational individualised medicine.

In an interview to CBS News, Dr. Anna Barker, former Deputy Director of the National Cancer Institute (U.S.A), explains in simple terms the basics of Bioinformatics and its applications to Cancer Research.

Key achievements

  • Identified a blood protein panel to recognise people in the early stages of Alzheimer's before symptoms appear. Read more...
  • Introduced a hallmark of cancer based on the changes of information theory quantifiers. Read more...
  • Proved the usefulness of an information theory-driven methodology by applying the technique to the identification of Alzheimer's Disease biomarkers. Read more...
  • Founded and organized the Inaugural Biomarker Discovery Meeting at Shoal Bay (2010). Read more...
  • Identified new multiple sclerosis susceptibility loci on chromosomes 12 and 20 ( Nature Genetics 2009). Read more...
  • Developed the first transcription factor map that can explain most of the gene expression variation observed in the gene expression molecular signatures for relapse remitting, primary progressive, and secondary progressive multiple sclerosis. Read more...
  • Developed a novel mathematical model, and an associated solution procedure based on combinatorial optimization techniques, to identify optimal drug combinations for cancer therapeutics. Read more...
  • Using a panel of abundances 120 signalling proteins on archived plasma samples, developed a novel mathematical method for biomarker discovery that led to the five-protein biomarker molecular signature for clinical Alzheimer's disease and developed classifiers that predict with 96% total accuracy the onset of the illness. Read more...
  • Developed the first method to distinguish childhood absence epilepsy from controls by the analysis of their background. Read more...